| # | Title | Journal | Year | Citations |
|---|
|
| 1 | Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? | Nature Reviews Drug Discovery | 2009 | 4,469 |
| 2 | Recent advances with liposomes as pharmaceutical carriers | Nature Reviews Drug Discovery | 2005 | 4,431 |
| 3 | Engineering precision nanoparticles for drug delivery | Nature Reviews Drug Discovery | 2021 | 3,830 |
| 4 | Nanoparticle therapeutics: an emerging treatment modality for cancer | Nature Reviews Drug Discovery | 2008 | 3,790 |
| 5 | MicroRNA therapeutics: towards a new era for the management of cancer and other diseases | Nature Reviews Drug Discovery | 2017 | 3,706 |
| 6 | Can the pharmaceutical industry reduce attrition rates? | Nature Reviews Drug Discovery | 2004 | 3,568 |
| 7 | Therapeutic potential of resveratrol: the in vivo evidence | Nature Reviews Drug Discovery | 2006 | 3,336 |
| 8 | Cellular processing of platinum anticancer drugs | Nature Reviews Drug Discovery | 2005 | 3,264 |
| 9 | Strategies in the design of nanoparticles for therapeutic applications | Nature Reviews Drug Discovery | 2010 | 3,195 |
| 10 | Targeting multidrug resistance in cancer | Nature Reviews Drug Discovery | 2006 | 3,145 |
| 11 | How many drug targets are there? | Nature Reviews Drug Discovery | 2006 | 3,131 |
| 12 | The dawning era of polymer therapeutics | Nature Reviews Drug Discovery | 2003 | 2,993 |
| 13 | Neurodegenerative diseases and oxidative stress | Nature Reviews Drug Discovery | 2004 | 2,992 |
| 14 | Effect of pegylation on pharmaceuticals | Nature Reviews Drug Discovery | 2003 | 2,989 |
| 15 | The druggable genome | Nature Reviews Drug Discovery | 2002 | 2,964 |
| 16 | Drug repurposing: progress, challenges and recommendations | Nature Reviews Drug Discovery | 2019 | 2,956 |
| 17 | Membrane transporters in drug development | Nature Reviews Drug Discovery | 2010 | 2,952 |
| 18 | mRNA vaccines — a new era in vaccinology | Nature Reviews Drug Discovery | 2018 | 2,921 |
| 19 | Docking and scoring in virtual screening for drug discovery: methods and applications | Nature Reviews Drug Discovery | 2004 | 2,858 |
| 20 | How to improve R&D productivity: the pharmaceutical industry's grand challenge | Nature Reviews Drug Discovery | 2010 | 2,851 |
| 21 | Modulation of oxidative stress as an anticancer strategy | Nature Reviews Drug Discovery | 2013 | 2,847 |
| 22 | Carbonic anhydrases: novel therapeutic applications for inhibitors and activators | Nature Reviews Drug Discovery | 2008 | 2,772 |
| 23 | Extracellular vesicles: biology and emerging therapeutic opportunities | Nature Reviews Drug Discovery | 2013 | 2,707 |
| 24 | Knocking down barriers: advances in siRNA delivery | Nature Reviews Drug Discovery | 2009 | 2,700 |
| 25 | Anticancer activities of histone deacetylase inhibitors | Nature Reviews Drug Discovery | 2006 | 2,608 |
| 26 | Drug repositioning: identifying and developing new uses for existing drugs | Nature Reviews Drug Discovery | 2004 | 2,565 |
| 27 | Natural products in drug discovery: advances and opportunities | Nature Reviews Drug Discovery | 2021 | 2,404 |
| 28 | Design and development of polymers for gene delivery | Nature Reviews Drug Discovery | 2005 | 2,317 |
| 29 | Targeting the phosphoinositide 3-kinase pathway in cancer | Nature Reviews Drug Discovery | 2009 | 2,274 |
| 30 | Understanding biofilm resistance to antibacterial agents | Nature Reviews Drug Discovery | 2003 | 2,260 |
| 31 | Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer | Nature Reviews Drug Discovery | 2004 | 2,254 |
| 32 | Approaches to treat immune hot, altered and cold tumours with combination immunotherapies | Nature Reviews Drug Discovery | 2019 | 2,229 |
| 33 | Drugs for bad bugs: confronting the challenges of antibacterial discovery | Nature Reviews Drug Discovery | 2007 | 2,218 |
| 34 | The nitrate–nitrite–nitric oxide pathway in physiology and therapeutics | Nature Reviews Drug Discovery | 2008 | 2,152 |
| 35 | The evolving role of natural products in drug discovery | Nature Reviews Drug Discovery | 2005 | 2,073 |
| 36 | The influence of drug-like concepts on decision-making in medicinal chemistry | Nature Reviews Drug Discovery | 2007 | 2,027 |
| 37 | Angiogenesis: an organizing principle for drug discovery? | Nature Reviews Drug Discovery | 2007 | 1,976 |
| 38 | The re-emergence of natural products for drug discovery in the genomics era | Nature Reviews Drug Discovery | 2015 | 1,973 |
| 39 | Protein kinases — the major drug targets of the twenty-first century? | Nature Reviews Drug Discovery | 2002 | 1,971 |
| 40 | Trends in GPCR drug discovery: new agents, targets and indications | Nature Reviews Drug Discovery | 2017 | 1,922 |
| 41 | Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery | Nature Reviews Drug Discovery | 2005 | 1,883 |
| 42 | Aptamers as therapeutics | Nature Reviews Drug Discovery | 2010 | 1,850 |
| 43 | The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics | Nature Reviews Drug Discovery | 2011 | 1,825 |
| 44 | Peroxynitrite: biochemistry, pathophysiology and development of therapeutics | Nature Reviews Drug Discovery | 2007 | 1,773 |
| 45 | Metabonomics: a platform for studying drug toxicity and gene function | Nature Reviews Drug Discovery | 2002 | 1,756 |
| 46 | Delivery technologies for cancer immunotherapy | Nature Reviews Drug Discovery | 2019 | 1,745 |
| 47 | Protein therapeutics: a summary and pharmacological classification | Nature Reviews Drug Discovery | 2008 | 1,740 |
| 48 | A comprehensive map of molecular drug targets | Nature Reviews Drug Discovery | 2017 | 1,736 |
| 49 | Cyclodextrin-based pharmaceutics: past, present and future | Nature Reviews Drug Discovery | 2004 | 1,687 |
| 50 | Hydrogen sulphide and its therapeutic potential | Nature Reviews Drug Discovery | 2007 | 1,653 |
